Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
Research & Drug Development
Testing Ion Channel Function
The electrophysiological patch clamp technique is the most direct method to show effects of drugs on ion channels in the cell membrane, and as such it remains essential as a secondary screen to the fluorescence assay. Furthermore, screening by patch clamp may be the first choice for ion channel targets, as it is the only useful technique for use-dependent drug-channel interactions. Currently Newron has a specialized Laboratory for Electrophysiological evaluations, including a TEVC platform for High Throughput Screening and patch clamp instruments.
Electrophysiological screening is conducted early in the Company's Discovery process and allows to cost-effectively decide whether or not to advance a drug candidate, as it allows to select state and frequency dependant blockers, with improved safety and tolerability profiles.